<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03669627</url>
  </required_header>
  <id_info>
    <org_study_id>CT18</org_study_id>
    <nct_id>NCT03669627</nct_id>
  </id_info>
  <brief_title>CT18 Infant Influenza Priming Study in Vaccine Naive Infants</brief_title>
  <official_title>A Randomized Controlled Observer Blind Trial to Compare the Immunogenicity and Acceptability of a MF59-adjuvanted Influenza Vaccine Compared to an Inactivated Influenza Vaccine as a Preferred Influenza Vaccine Priming Strategy for Naive Infants 6 to &lt;24 Months of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Canadian Immunization Research Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Provincial Health Services Authority</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>McGill University Health Centre/Research Institute of the McGill University Health Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Université de Montréal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canadian Center for Vaccinology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CHU de Quebec-Universite Laval</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dalhousie University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Canadian Immunization Research Network</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates whether priming influenza naive infants, age six to 23 months, with a
      MF59-adjuvanted (oil in water emulsion) influenza vaccine is preferred to priming with an
      inactivated unadjuvanted influenza vaccine. All participants will receive a priming vaccine,
      either MF59-adjuvanted trivalent influenza vaccine (aTIV) or unadjuvanted quadrivalent
      influenza vaccine (QIV). For the booster shot the following year, two thirds of participants
      will receive QIV and one third will receive MF59-adjuvanted vaccine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Children under 24 months of age suffer from an influenza burden (high morbidity and
      mortality) similar to that of the elderly, and have been identified as a high priority target
      for vaccination programs by Canada's National Advisory Committee on Immunization. There is
      evidence that a person's first exposure to influenza antigens may have long-term implications
      for protection.

      This is a randomized, controlled, observer-blind study that will assign participants to one
      of three groups. Group 1 will receive MF59-adjuvanted influenza vaccine (two doses one month
      apart) in the fall of year 1, followed by QIV (one dose) in the fall of year 2. Group 2 will
      receive QIV (two doses one month apart) in the fall of year 1, followed by QIV (one dose) in
      the fall of year 2. Group 3 will receive MF59-adjuvanted IV (two doses one month apart) in
      the fall of year 1, followed by MF59-adjuvanted IV (one dose) in the fall of year 2.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2018</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be randomly assigned to one of three groups: Group 1 will receive aTIV as a primer and QIV as a booster, Group 2 will receive QIV as both primer and booster, and Group 3 will receive aTIV as both primer and booster.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Investigator)</masking>
    <masking_description>Observer-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Serum hemagglutination inhibition (HI) antibody titers</measure>
    <time_frame>Before and after priming with the various vaccine combinations at day 393.</time_frame>
    <description>Serum HI antibodies to influenza antigens A/H3N2, A/H1N1, and B Yamagata and Victoria lineages will be used to calculate the seroconversion rate and the seroprotection rates.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (AEs)</measure>
    <time_frame>Days 0 to 545</time_frame>
    <description>Measure local and systemic solicited and unsolicited adverse events following each vaccine dose, and severe AE throughout the study.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Vaccine acceptability: parent/Legally Authorized Representative (LAR) questionnaire</measure>
    <time_frame>Days 56, 180, 393, and 545</time_frame>
    <description>The Acceptability Questionnaire measures parental opinions about side effects of the study vaccines. There are four questions with a scale range evaluating degree of certainty and one open-ended question with a free text response. There is no total score.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cell-Mediated Immunity</measure>
    <time_frame>Days 0, 56, 180, 365, 393, 545</time_frame>
    <description>To assess cell mediated immune responses to three influenza immunization two priming schedules in vaccine naïve infants.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Group 1: aTIV primer, QIV booster</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Two doses (0.25 mL) aTIV (FLUAD )received one month apart in year 1. One dose (0.5 mL) QIV (Fluzone) received as booster in year 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: QIV primer, QIV booster</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Standard of care control group:
Two doses (0.5 mL) QIV (Fluzone) received one month apart in year 1. One dose (0.5 mL) QIV (Fluzone) received as booster in year 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: aTIV primer, aTIV booster</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm is experimental in that some participants will be receiving the MF59-adjuvanted TIV (FLUAD) in year two of the study, after the age of two years, which is off label.
Two doses (0.25 mL) TIV (FLUAD) received one month apart in year 1. One dose (0.25 mL) TIV (FLUAD) received as booster in year 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aTIV Primer</intervention_name>
    <description>MF59-adjuvanted trivalent influenza virus primer: 2 doses (0.25mL) one month apart</description>
    <arm_group_label>Group 1: aTIV primer, QIV booster</arm_group_label>
    <arm_group_label>Group 3: aTIV primer, aTIV booster</arm_group_label>
    <other_name>FLUAD Pediatric®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>QIV Primer</intervention_name>
    <description>Unadjuvanted quadrivalent influenza vaccine primer: 2 doses (0.5mL) one month apart</description>
    <arm_group_label>Group 2: QIV primer, QIV booster</arm_group_label>
    <other_name>Fluzone® Quadrivalent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aTIV Booster</intervention_name>
    <description>MF59-adjuvanted influenza virus vaccine booster: 1 dose (0.25mL), year 2</description>
    <arm_group_label>Group 3: aTIV primer, aTIV booster</arm_group_label>
    <other_name>FLUAD Pediatric®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>QIV Booster</intervention_name>
    <description>Unadjuvanted quadrivalent influenza vaccine booster: 1 dose (0.5mL), year 2</description>
    <arm_group_label>Group 1: aTIV primer, QIV booster</arm_group_label>
    <arm_group_label>Group 2: QIV primer, QIV booster</arm_group_label>
    <other_name>Fluzone® Quadrivalent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Parent/LAR is willing and able to give informed consent for participation in the
             trial.

          -  Male or Female, aged six months to 23 months.

          -  In the Investigator's opinion, is able and willing to comply with all trial
             requirements.

        Exclusion Criteria:

          -  Any significant disease or disorder which, in the opinion of the Investigator, may
             either put the participants at risk because of participation in the trial, or may
             influence the result of the trial, or the participant's ability to participate in the
             trial.

          -  Participant in another research trial involving an investigational product or medical
             device in the prior 12 weeks.

          -  Prior receipt of an influenza vaccine

          -  History of laboratory-confirmed influenza infection, by parent/LAR report

          -  Hypersensitivity to any vaccine component of products used in this study (see product
             monographs)

          -  Immunodeficiency or autoimmune disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>23 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joanne M Langley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dalhousie University, Canadian Center for Vaccinology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Soren Gantt, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>BC Children's Hospital, UBC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jill Mutch, BScN</last_name>
    <phone>902-470-3860</phone>
    <email>jill.mutch@iwk.nshealth.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Vaccine Evaluation Center, BC Children's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4H4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Soren Gantt, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>IWK Health Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3K 6R8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Brown, RN</last_name>
      <phone>902-470-7015</phone>
      <email>catherine.brown@iwk.nshealth.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Institute of the McGill University health Centre</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H9H 4Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Caroline Quach, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Équipe de recherche en vaccination CHU de Québec-Université Laval</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <zip>G1E 7G9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marc Dionne, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>September 5, 2018</study_first_submitted>
  <study_first_submitted_qc>September 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2018</study_first_posted>
  <last_update_submitted>August 11, 2019</last_update_submitted>
  <last_update_submitted_qc>August 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Canadian Immunization Research Network</investigator_affiliation>
    <investigator_full_name>Joanne Langley</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>infants</keyword>
  <keyword>priming</keyword>
  <keyword>Fluad</keyword>
  <keyword>Fluzone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

